Both small and large pharmaceutical firms are tapping the low-cost global pharmaceutical outsourcing market for both research and manufacturing.  It is estimated that the global outsourcing market will surpass $53 billion by 2010. 

As you consider your outsourcing options, Strategic Research Institute’s Global Biopharmaceutical Outsourcing provides you with in-depth explorations of the hottest topics in the market in your own back yard.  This two day, intensive event covers the essential and vital information you need to keep your projects on track while minimizing costs. 

Delve into the key issues:

• Develop and understand local regulatory practices with sites and investigators in China, India, Brazil and Europe
• Outsourcing capabilities and critical IP in China, India, Hong Kong, Taiwan, Singapore, Latin America and Europe
• Overcome obstacles in study start-up: per subject costing, investigator contract and budget negotiations, regulatory document collection and consultant agreement negotiation
• Selecting the right clinical and preclinical approaches: Individual and Multi-project outsourcing
• Streamlining outsourcing partnerships: who owns what and who bears the liability
• Outsourcing drug safety and toxicology to China
• CRO evaluations and due diligence

Plus:

• Robert Freeman, Ph.D., Texas A&M Health Science Center College of Pharmaceuticals, Kingsville, TX on “Sponsors and CROs: The Dual Perspective on Outsourcing”
• “The Risks and Rewards of Collaborations Case Study”, an in-depth review of the unique collaborations between ICON, INC Research and Pfizer where the three parties work together as a team to overcome obstacles to the study start up process
• “Preclinical Outsourcing to China: Our Working Experience of Three Years”, frontline advice from Frontier Biosciences, Inc. 

For questions on content or to join the speaker faculty, please contact Judy Kelly, Senior Event Director, at 212-967-0095 ext 241 or jkelly@srinstitute.com

Meet, Network & Present to the BEST industry has to offer!